To better comprehend underlying mechanisms driving a differential response to immunotherapy, further investigations are warranted into the interaction between our oncogenic drivers and tumor protein expression markers (e.g., TTF-1, NapA, PD-L1) to improve patient outcomes. This evidence concerns the gene TTF1 and neoplasm.